FDA’s Advisory Committee Conflict of Interest Policy Too Restrictive, Nissen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Cleveland Clinic cardiologist says FDA conflict of interest guidelines would prevent him from a second term on an advisory committee.
You may also be interested in...
FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.
FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.
U.S. FDA Confirms Daiichi/Lilly Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
As preparations get underway for the Feb. 3 advisory committee review of Lilly and Daiichi Sankyo's platelet inhibitor prasugrel, one indicator of the drug's prospects will be the individuals who are asked by U.S. FDA to serve on the expert panel